Hematologist
CION Cancer Clinics
CAR-T cell therapy as second-line treatment for DLBCL | CION Cancer Clinics
CAR-T is now often the recommended second treatment when DLBCL comes back within a year of first treatment or never responded. Your own T cells are collected, changed to find the lymphoma and returned in one infusion. It carries serious but usually manageable reactions and needs weeks near a specialist centre. This page explains who it suits, the steps, the risks and what families plan for. At CION Cancer Clinics, our haematology team plans myeloma and lymphoma care with you, discussed at a tumour board and explained in plain words.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- When is CAR-T used as second-line treatment for DLBCL?
- What happens from referral to infusion?
- Who is CAR-T suited to, and who is it not?
- How does CAR-T compare with salvage chemotherapy and transplant?
- What do families often misunderstand about CAR-T?
- What should you plan for, and what can this page not tell you?
- Common questions about CAR-T for relapsed DLBCL
The short answer
When is CAR-T used as second-line treatment for DLBCL?
CAR-T is now often recommended as the second treatment for DLBCL that comes back within a year of first treatment, or that never responded to it. In large trials, it did better than the older route of salvage chemotherapy and a stem cell transplant for this group.
What CAR-T actually is
Your own T cells, a type of white blood cell, are collected from your blood. In a laboratory they are changed so they can recognise a marker called CD19 on the lymphoma cells. They are multiplied and returned through a drip, where they seek out and attack the lymphoma.
Why timing decides so much
Lymphoma that returns early, or does not respond, tends to resist more chemotherapy. That is why salvage chemotherapy and transplant work less well in this group, and why CAR-T moved earlier. When the lymphoma comes back later, salvage chemotherapy and transplant remain a reasonable option.
A one-time treatment with a long lead-up
The infusion itself is given once. But the whole process, from referral to making the cells to close watching afterwards, takes weeks, and it happens only at specialist centres approved to give it.
The process
What happens from referral to infusion?
Assessment at a CAR-T centre
Scans, blood tests and checks of the heart, lungs and brain confirm whether you are fit enough, and whether the lymphoma still carries the target marker.
Collecting your T cells
A machine takes blood from a vein, keeps the white cells and returns the rest. It takes some hours and feels like a long blood donation.
Bridging treatment
While the cells are being made, you may receive steroids, chemotherapy or radiotherapy to keep the lymphoma under control.
Lymphodepletion
A few days of mild chemotherapy lower your own white cells, making room for the CAR-T cells to grow.
Infusion and close watching
The cells go in through a drip in under an hour. You are then watched closely, in hospital or very nearby, for several weeks.
Not sure whether this applies to you?
Ask an oncologistWeighing it up
Who is CAR-T suited to, and who is it not?
The decision is made case by case, usually at a tumour board, and often with the CAR-T centre.
Often suited to
Adults whose DLBCL came back early or did not respond, who are active day to day and whose heart, lungs and kidneys are working reasonably well.
Not suited to transplant, but fit enough for CAR-T
Some people who could not cope with a high-dose transplant can still have CAR-T, because it does not involve high-dose chemotherapy. This is judged individually.
Often not suited to
The risks may outweigh the benefit in some situations.
The team thinks carefully about
- Active, uncontrolled infection
- Serious heart, lung or nerve illness
- Lymphoma in the brain
- Being very unwell or bedbound
Late relapse
When DLBCL returns a long time after first treatment, salvage chemotherapy and transplant are often tried first, with CAR-T kept as a later option. If salvage chemotherapy does not work, CAR-T may still be offered at that point, so the door is not closed.
Side by side
How does CAR-T compare with salvage chemotherapy and transplant?
CAR-T
Salvage chemotherapy and transplant
Favoured when relapse is early or there was no response
Standard when relapse is later and salvage works
One infusion of your own changed T cells
Several cycles, then high-dose chemotherapy and stem cell return
Main risks are immune reactions and infections
Main risks are infection and very low counts
Offered at fewer centres, often with a waiting period
Available at more transplant units
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
!
One thing that cannot wait
In the weeks after CAR-T, a fever, shivering, dizziness, breathlessness, new confusion, trouble finding words, shaking, unusual sleepiness or a fit needs same-day help. These can be signs of cytokine release syndrome or a nerve reaction. Call the CAR-T centre's emergency number at once, or go to the nearest emergency department or call 108, and say the person has had CAR-T.
Commonly believed
What do families often misunderstand about CAR-T?
"CAR-T is only for when everything else has failed."
That used to be true. Trials have moved it earlier, so for early relapse it is now often the second treatment, not the last. Asking about it at the first sign of relapse matters.
"It is a gentle treatment because it is only cells."
CAR-T can cause serious reactions: high fevers, drops in blood pressure, confusion and prolonged low blood counts. Most reactions are manageable at an experienced centre, but it is not a mild treatment, and close watching is essential.
"It is not available in India at all."
CAR-T is available in India, including a product developed in India, at a limited number of specialist centres. Access, waiting time and cost differ, so ask early rather than assuming it is out of reach.
"If the first scan after CAR-T is not clear, it has failed."
Responses can take time to settle, and inflammation can glow on early scans. Your team will judge the response over follow-up scans rather than on one picture alone.
Being straight with you
What should you plan for, and what can this page not tell you?
This page cannot tell you whether CAR-T is right for you or how well it would work. That depends on how soon the lymphoma returned, its features on biopsy, your fitness and how quickly the cells can be made. It also cannot give you a cost. CAR-T is expensive, prices differ between products and centres, and scheme cover is limited and changing.
What the family needs to plan for
You will usually need to stay within easy reach of the CAR-T centre for several weeks after the infusion, with a caregiver with you all the time. Driving is not allowed for some weeks because of the risk of sudden confusion. Plan leave, accommodation and who will be the caregiver before the date is fixed.
When CAR-T is not possible
If you are not fit enough, cannot reach a centre, or the cells cannot be made, other options remain. These include bispecific antibodies, salvage chemotherapy, clinical trials, and treatment aimed at control and comfort. Your haematologist will explain which of these suits you.
How CION helps
CION does not make or give CAR-T cells. CION's haematology team reviews your biopsy, scans and treatment history, discusses the case at a tumour board, and coordinates assessment and referral with qualified CAR-T centres. Ask for a written estimate and check current Aarogyasri, PM-JAY, CGHS, ECHS, EHS or insurance terms before you commit.
Questions we are asked
Common questions about CAR-T for relapsed DLBCL
My mother's lymphoma came back quickly. Should we ask about CAR-T?
Yes. When DLBCL returns within a year of first treatment or never responded, CAR-T is often the recommended next step. Ask the haematologist early, because assessment and making the cells take time. Bring her biopsy, all PET reports and the dates of her first treatment.
How long does it take to make the CAR-T cells?
Usually a few weeks from collection to the cells being ready, and slot availability can add more. Bridging treatment is often given during this wait to keep the lymphoma in check. The CAR-T centre will give you a timeline once the cells have been collected.
What is cytokine release syndrome?
It is a strong immune reaction as the CAR-T cells become active. It often starts with fever and can cause low blood pressure or breathlessness. Centres treat it with fluids, oxygen and medicines such as tocilizumab or steroids. This is why you stay close to the centre in the early weeks.
Can CAR-T affect the brain?
Some people develop a nerve reaction, with confusion, trouble speaking, shaking or, rarely, fits. It usually appears in the first weeks and is usually reversible with prompt treatment. The team checks handwriting and simple questions daily. Tell them about any change straight away.
Will the blood counts stay low afterwards?
Low counts can last for weeks or longer, and infections are more likely for months. Normal B cells, which make antibodies, may stay low for a long time. Some people need antibody drips and preventive medicines. The team will set up regular blood tests after discharge.
Can older people have CAR-T?
Age alone does not rule it out. Fitness, heart and lung health, other illnesses and the ability to have a caregiver nearby matter more. Some older adults who could not manage a transplant are still considered for CAR-T. The centre makes this judgement after a full assessment.
Is CAR-T covered by Aarogyasri or insurance?
Cover varies a lot. Some insurance policies include it as an advanced treatment, often with limits, and government scheme cover is limited and changing. Ask the CAR-T centre's insurance desk to check your Aarogyasri, PM-JAY, CGHS, ECHS, EHS or policy terms in writing before you commit.
Can CION help us decide between CAR-T and transplant?
Yes. CION's haematology team reviews the biopsy, scans and first treatment history, discusses the case at a tumour board, and explains which route fits. The team coordinates assessment and referral with qualified CAR-T and transplant centres, and stays involved in follow-up.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- NICE — Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and high-grade B-cell lymphoma that relapses within 12 months after first-line chemoimmunotherapy (TA895)
- National Cancer Institute — CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers
- American Cancer Society — CAR T-cell Therapy and Its Side Effects
- Leukemia & Lymphoma Society — Non-Hodgkin Lymphoma
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Salvage Chemotherapy and Autologous Transplant in DLBCLThe other second-line route, for later relapseBispecific Antibodies in Relapsed LymphomaAn option after CAR-T or when CAR-T is not possibleImmunotherapy guideHow immune-based cancer treatments workAggressive B-Cell LymphomaThe overview of this lymphoma group
Talk to us
Wondering whether CAR-T is an option?
Share the biopsy and scan reports. CION's haematology team will review them and help you reach a qualified CAR-T centre if it fits. One helpline serves every CION centre.